QINIU Sets 15 May 2026 AGM; Board Seeks 10% Share Buyback and 20% Issuance Mandates

QINIU (02567) will convene its 2026 annual general meeting on 15 May 2026 at 2:00 p.m. in Shanghai’s Zhangjiang AI Island. Shareholders will vote on six ordinary resolutions covering financial reporting, board composition, auditor re-appointment and new capital management mandates.

Key agenda items:

• Financials: Adoption of the audited consolidated financial statements and the directors’ and auditor’s reports for the year ended 31 December 2025.

• Board continuity: Executive directors Mr Xu Shiwei and Ms Chen Yiling are standing for re-election; directors’ remuneration will remain subject to board determination.

• Auditor: Re-appointment of Ernst & Young, with remuneration to be set by the board.

• Capital return: Authorisation for the board to repurchase up to 10% of issued shares (excluding any treasury shares) on the Hong Kong Stock Exchange or other recognised bourses during the mandate period ending at the next AGM or its earlier revocation.

• Capital raising: A separate mandate will allow the board to allot and issue new shares— or transfer treasury shares—of up to 20% of the company’s issued share capital, excluding shares issued under rights issues, convertible securities, share option schemes or scrip dividends.

• Mandate extension: Subject to the above approvals, the issuance limit may be increased by the number of shares actually repurchased, effectively adding up to another 10% of share capital to the issuance capacity.

Administrative arrangements:

• Shareholders’ register will be closed from 12 May to 15 May 2026; the record date is 15 May 2026. Share transfer documents must be lodged with Tricor Investor Services by 4:30 p.m. on 11 May 2026 for voting eligibility.

• Proxy forms must be submitted at least 48 hours before the meeting.

• The meeting will proceed on the scheduled date regardless of weather conditions.

Board composition as of the notice date comprises Chairman and Executive Director Mr Xu Shiwei, Executive Director Ms Chen Yiling, Non-executive Director Mr Lyu Guihua, and Independent Non-executive Directors Mr Wei Shaojun, Mr Zhou Zheng and Dr Shi Qing.